Share on LinkedInShare on LinkedIn

ARTICLE · 25 MAY 2011

Australian Federal Court Refuses Aventis' Application for Interlocutory Relief

The Federal Court of Australia recently refused an application for an interlocutory injunction by Aventis because ten months had elapsed between Aventis’ realisation of allegedly infringing conduct by two generic manufacturers and its subsequent application for injunctive relief from such conduct (Interpharma Pty Ltd v Aventis Pharma SA [2011] FCA 32).

AustraliaIntellectual Property

There is no time like the present

The Federal Court of Australia recently refused an application for an interlocutory injunction by Aventis because ten months had elapsed between Aventis' realisation of allegedly infringing conduct by two generic manufacturers and its subsequent application for injunctive relief from such conduct (Interpharma Pty Ltd v Aventis Pharma SA [2011] FCA 32).

Aventis realised in February 2010 that two generic manufacturers, Interpharma and Hospira, intended to market generic docetaxel (taxotere) compositions following the expiry of Aventis' docetaxel compound patent (AU591309) having on 6 February 2011. Between February and May 2010, Aventis communicated with the generic manufacturers and repeatedly threatened to apply for injunctive relief, unless the generic manufacturers provided undertakings that their conduct would not infringe Aventis' Australian patent covering specific docetaxel compositions (AU666859; having an expiry date of 3

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from